Adefovir dipivoxil (Hepsera): Discontinuation
Gilead Sciences (NZ) have notified PHARMAC that they will stop making adefovir dipivoxil (Hepsera).
About this discontinuation
Adefovir dipivoxil is an antiviral medicine used to treat Hepatitis B. There are fewer than 40 people in New Zealand taking this medicine.
Supplies of adefovir dipivoxil will run out later in 2020.
We know that changing medicines can be disruptive. We apologise for any inconvenience.
Information for people taking adefovir dipivoxil
You will need to talk to your prescriber about an alternative to adefovir dipivoxil. There are other funded alternatives to treat hepatitis B. Your health care professional knows you and your clinical circumstances best. They are in the best place to advise you on the options.
Information for prescribers
Any of your patients taking adefovir dipivoxil will need to change to a different antiviral treatment by 1 November 2020.
Prescribers will need to:
- ensure no new patients are started on adefovir dipivoxil
- transition patients currently on adefovir dipivoxil to alternative treatments as soon as possible.
There are other alternative currently funded treatments available to treat Hepatitis B.
Information for pharmacists
Please advise patients taking adefovir dipivoxil to see their prescriber so that they can change to a different Hepatitis B treatment as soon as possible.
We have advised prescribers to transition their patients to an alternative treatment.
- Late 2020: Stock of adefovir dipivoxil runs out
- 28 February 2021: Existing stock of adefovir dipivoxil expires
- 1 March 2021: Adefovir dipivoxil will be delisted 1 March from 2021
Who to contact
If you have any questions about this discontinuation, email email@example.com
Last updated: 13 August 2020